-
Mashup Score: 0
AUA 2023, SunRISe-1 trial, Bacillus Calmette-Guerin (BCG), BCG Unresponsive High-Risk Non–muscle-Invasive Bladder Cancer (NMIBC), TAR-200 in Combination With Cetrelimab, TAR-200 monotherapy, Cetrelimab, gemcitabine, efficacy of TAR-200 monotherapy.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Instagram - 2 year(s) ago
rafavidal78 697 posts · 595 followers
Source: www.instagram.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Login • Instagram - 3 year(s) ago
Welcome back to Instagram. Sign in to check out what your friends, family & interests have been capturing & sharing around the world.
Source: www.instagram.comCategories: Cardiologists, Latest HeadlinesTweet
First results from #SunRISe-1 in patients with BCG unresponsive high-risk #NMIBC receiving TAR-200 in combination with cetrelimab, TAR-200, or cetrelimab alone. Presented by @siadaneshmand @KeckMedUSC. #AUA23 written coverage by @rksayyid @UofT > https://t.co/Hm7fRqozMZ https://t.co/W3pQVOH9XW